2021
DOI: 10.1111/ddg.14317
|View full text |Cite
|
Sign up to set email alerts
|

Therapy understanding and health related quality of life in stage III/IV melanoma patients treated with novel adjuvant therapies

Abstract: Summary Objective Our aims were to investigate the motivation for therapy, the understanding and valuation of potential treatment toxicities in melanoma patients offered adjuvant therapies. Methods Between September 2018 and September 2019 49 adjuvant patients with stage III and IV melanoma received a self‐created, pre‐treatment questionnaire. Furthermore, the patients were handed out the REPERES‐G, EQ‐5D‐3L and EORTC QLQ C‐30 questionnaires. Results Eight patients (18.3 %) decided against adjuvant therapy (me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
8
0
3

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 20 publications
2
8
0
3
Order By: Relevance
“…Risk scores from gene or immunohistochemical signatures have the potential to tailor adjuvant therapy independent of the histopathological criteria of the primary melanoma or the sentinel lymph node results. Acceptance rate of adjuvant therapies is high in stage III melanoma patients [ 37 ]. Additionally, further follow-up examinations after three years with lymph node sonography and computer tomography should be discussed in patients classified with high-risk scores.…”
Section: Discussionmentioning
confidence: 99%
“…Risk scores from gene or immunohistochemical signatures have the potential to tailor adjuvant therapy independent of the histopathological criteria of the primary melanoma or the sentinel lymph node results. Acceptance rate of adjuvant therapies is high in stage III melanoma patients [ 37 ]. Additionally, further follow-up examinations after three years with lymph node sonography and computer tomography should be discussed in patients classified with high-risk scores.…”
Section: Discussionmentioning
confidence: 99%
“…The publication and reporting of rare, adverse events in the appropriate registries will help to further improve handling of this group of substances. Providing patients with detailed information on adverse effects, which may be irreversible, is necessary to enable informed decision making and to further improve the acceptance of adjuvant immunotherapy [17].…”
Section: Clinical Lettermentioning
confidence: 99%
“…Tumor deposits were detected in one of three lymph nodes, without signs of capsular invasion. This case was discussed in our interdisciplinary tumor board, and an off-label adjuvant anti-programmed cell death protein 1 (PD-1) monotherapy with pembrolizumab 2 mg/kg bodyweight every three weeks for one year was offered, despite potential side effects [4]. Thus far, the patient has received the first five doses and has tolerated the therapy well.…”
Section: Clinical Lettermentioning
confidence: 99%